Abstract
A 52-year-old woman with ulcerative colitis was admitted to our hospital for an ulcerative colitis flare-up under salazosulfapyridine therapy. The symptoms improved with high-dose corticosteroids. After prednisolone was tapered to 10 mg, the frequency of diarrhea increased. The diarrhea was accompanied by joint pain and a skin ulcer with abscess formation, which was diagnosed to be pyoderma gangrenosum. The patient was started on adalimumab. A positive response to the adalimumab therapy was observed after 2 weeks, during which time the ulcerative skin lesion healed completely, however, colonic mucosal healing was achieved at 2 months. Therefore, adalimumab appears to be an effective therapeutic option for patients with ulcerative colitis-associated pyoderma gangrenosum.
MeSH terms
-
Adalimumab / administration & dosage
-
Adalimumab / therapeutic use*
-
Adrenal Cortex Hormones / administration & dosage*
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use*
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Colitis, Ulcerative / complications
-
Colitis, Ulcerative / drug therapy*
-
Female
-
Humans
-
Middle Aged
-
Prednisolone / administration & dosage*
-
Pyoderma Gangrenosum / drug therapy*
-
Pyoderma Gangrenosum / etiology
-
Skin Ulcer / complications
-
Skin Ulcer / drug therapy*
-
Skin Ulcer / pathology
-
Sulfasalazine / administration & dosage
-
Treatment Failure
-
Treatment Outcome
Substances
-
Adrenal Cortex Hormones
-
Anti-Inflammatory Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Sulfasalazine
-
Prednisolone
-
Adalimumab